The Galien Forum USA 2020

PANEL
1

Chair
George Yancopoulos
Founding Scientist, President & Chief Scientific Officer
Regeneron Pharmaceuticals

Panelists
Carl H. June, MD
Director, Center for Cellular Immunotherapies
Professor of Pathology and Laboratory Medicine
Director, Parker Institute for Cancer Immunotherapy
Perelman School of Medicine
University of Pennsylvania

Nancy Simonian, MD
President and Chief Executive Officer
Syros Pharmaceuticals

Panel Intro

Immunology from Both Sides: Oncology and Autoimmune Disease


George_YANCOPOULOS_P1 Chair
George Yancopoulos
Founding Scientist, President & Chief Scientific Officer
Regeneron Pharmaceuticals

George Yancopoulos has built and managed Regeneron since 1989, and is currently President and Chief Scientific Officer and has served on the board since 2001.  He, along with other members of his team, is the principal inventor of six FDA-approved drugs and foundational technologies.  Yancopoulos was named an Ernst & Young Entrepreneur of the Year and has been pivotal in creating the science-driven, collaborative and highly productive R&D culture at Regeneron, earning the company recognition as one of the “most innovative companies in the world” by Forbes magazine.  He was the 11th most highly cited scientist in the world in the 1990s. Yancoupolous attended the Bronx High School of Science and received his MD and PhD from Columbia University.


Carl_June_P1_1Carl H. June, MD
Director, Center for Cellular Immunotherapies
Professor of Pathology and Laboratory Medicine
Director, Parker Institute for Cancer Immunotherapy
Perelman School of Medicine, University of Pennsylvania

Carl H. June is the Richard W. Vague Professor in Immunotherapy ,Director of the Center for Cellular Immunotherapies and Director of the Parker Institute for Cancer Immunotherapy in the Perelman School of Medicine at the University of Pennsylvania. He maintains a research laboratory that studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy for cancer and chronic infection. In 2011, his research team published findings detailing a new therapy in which patients with refractory and relapsed chronic lymphocytic leukemia were treated with genetically engineered versions of their own T cells. The June laboratory has been highly productive with >500 publications, and a google scholar h-index of 147 with >83,000 citations.

The impact of this work has become widely recognized as a major turning point that is delivering on the long-held promise of cancer gene therapy. The CAR T cells invented in the June laboratory were awarded “Breakthrough Therapy” status by the FDA for acute leukemia in children and adults in 2014 and for adults with lymphoma in 2018. The CAR T cells invented in the June laboratory were approved by the FDA for acute leukemia in 2017 and afterwards, for diffuse large B cell lymphoma. These accomplishments have been recognized by the White House on several occasions.

June has published more than 500 manuscripts and is the recipient of numerous prizes and honors, including election to the Institute of Medicine in 2012 and the American Academy of Arts and Sciences in 2014, the Paul Ehrlich and Ludwig Darmstaedter Prize (shared w J. Allison), the Novartis Prize in Immunology (shared w Z. Eshhar and S. Rosenberg), the Karl Landsteiner Memorial award, the Karnofsky Prize from the American Society of Clinical Oncology, the Albany Medical Prize and a lifetime achievement award from the Leukemia and Lymphoma Society.


Nancy_SIMONIAN_P1Nancy Simonian, MD
President and Chief Executive Officer
Syros Pharmaceuticals

Nancy is the founding CEO of Syros and has an established track record of value creation in biotechnology. She has led the evolution of Syros from its inception into a publicly traded company with two drug candidates in clinical trials, a rich preclinical pipeline, and leading gene control platform. Prior to Syros, she was Chief Medical Officer at Millennium Pharmaceuticals, and previously, Vice President of Clinical Development at Biogen. Nancy has overseen the successful development of numerous medicines. Under Nancy’s leadership as Chief Medical Officer at Millennium, VELCADE became a mainstay of treatment for multiple myeloma. Nancy led development of Millennium’s clinical pipeline, including NINLARO for hematologic malignancies and ENTYVIO for inflammatory bowel disease. At Biogen, Nancy played a central role in developing AVONEX and TYSABRI for multiple sclerosis. Nancy started her career as an assistant professor at Harvard Medical School and neurology staff at Massachusetts General Hospital (MGH). She trained in neurology and internal medicine at MGH and graduated with a bachelor’s degree in biology from Princeton. She is currently a member of the board of directors of Evelo Biosciences, Seattle Genetics, the Biotechnology Innovation Organization (BIO) and the Damon Runyon Cancer Research Foundation.